Article
Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals.
Leukemia & lymphoma - 1 Apr 2020
Chua Chong C, Grigg Andrew, Singh Jasmine, Droogleever Mark P, Zhang Lan, Lim Andrew, Fong Chun Y, Ting Stephen B, Schwarer Anthony, Tiong Ing S, Wei Andrew H
Abstract excerpt
Recent regulatory approval of midostaurin, a FLT3 targeting small molecular inhibitor, will likely lead to increased use of midostaurin in combination with intensive chemotherapy for patients with FLT3-mutant AML. Translation of clinical trial results into everyday practice has its challenges. This study compared the relevance of the trial population and practices studied in the midostaurin registration study...
Topics
- Australia
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Staurosporine
- Tertiary Care Centers
- fms-Like Tyrosine Kinase 3